<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-biopharma-veteran-takes-her-ceo-cue" hreflang="en">Chutes & Ladders—Biopharma veteran takes her CEO Cue</a>
Shao-Lee Lin has been appointed as the new CEO of Cue Biopharma following the departure of former CEO Usman Azam, bringing extensive biopharma experience from her previous roles at Acelyrin, Amgen, and AbbVie. Additionally, Kyverna Therapeutics has hired Nadia Dac as chief commercial officer to prepare for the launch of its CAR-T therapy, while Anavex Life Sciences has promoted Terrie Kellmeyer to interim CEO after the ousting of Christopher Missling.
Kyverna Therapeutics' strategic appointment of Nadia Dac as chief commercial officer to lead the commercial strategy for their CAR-T therapy, which is poised to be the first approved for autoimmune diseases, signals a significant step in the commercialization of advanced therapies in this area. This move underscores the potential for investment opportunities in companies that are at the forefront of developing pioneering treatments for rare autoimmune conditions, particularly as Kyverna's phase 2 trials have shown promising results.